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Abstract
Background: Subclinical hypothyroidism (SCH) is a common condition in elderly people, defined as elevated serum
thyroid-stimulating hormone (TSH) with normal circulating free thyroxine (fT4). Evidence is lacking about the effect
of thyroid hormone treatment. We describe the protocol of a large randomised controlled trial (RCT) of
Levothyroxine treatment for SCH.
Methods: Participants are community-dwelling subjects aged ≥65 years with SCH, diagnosed by elevated TSH
levels (≥4.6 and ≤19.9 mU/L) on a minimum of two measures ≥ three months apart, with fT4 levels within
laboratory reference range. The study is a randomised double-blind placebo-controlled parallel group trial, starting
with levothyroxine 50 micrograms daily (25 micrograms in subjects <50Kg body weight or known coronary heart
disease) with titration of dose in the active treatment group according to TSH level, and a mock titration in the
placebo group. The primary outcomes are changes in two domains (hypothyroid symptoms and fatigue / vitality)
on the thyroid-related quality of life questionnaire (ThyPRO) at one year. The study has 80% power (at p = 0.025, 2-
tailed) to detect a change with levothyroxine treatment of 3.0% on the hypothyroid scale and 4.1% on the fatigue /
vitality scale with a total target sample size of 750 patients.
Secondary outcomes include general health-related quality of life (EuroQol), fatal and non-fatal cardiovascular
events, handgrip strength, executive cognitive function (Letter Digit Coding Test), basic and instrumental activities
of daily living, haemoglobin, blood pressure, weight, body mass index and waist circumference. Patients are
monitored for specific adverse events of interest including incident atrial fibrillation, heart failure and bone fracture.
(Continued on next page)
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Discussion: This large multicentre RCT of levothyroxine treatment of subclinical hypothyroidism is powered to
detect clinically relevant change in symptoms / quality of life and is likely to be highly influential in guiding
treatment of this common condition.
Trial registration: Clinicaltrials.gov NCT01660126; registered 8th June 2012.
Keywords: Subclinical hypothyroidism, Elderly, Randomised controlled trial, Levothyroxine, Quality of life, Thyroid disease
Background
Subclinical hypothyroidism (SCH) is defined as an ele-
vated serum thyroid-stimulating hormone (TSH) with
normal serum levels of free thyroxine (fT4) and few or
no hypothyroid symptoms [1]. Between 8 and 18% of
adults over 65 years have biochemical features of SCH,
the prevalence being higher among women [2]. SCH is a
possible contributor to multiple problems in older age.
From a biological point of view thyroid hormones have
multiple pleiotropic effects, acting as an essential regula-
tory factor in numerous physiological systems, including
the vascular tree and the heart [3], brain (including cog-
nition and mood) [4], skeletal muscle and bone [5].
Subjects with SCH do not have the full symptom
cluster of overt hypothyroidism; however they often
report non-specific symptoms such as tiredness, dry
skin, feeling cold, puffy eyes, constipation and cogni-
tive problems [6]. Muscle symptoms such as cramps,
weakness and myalgia are more common in SCH
than in euthyroid controls [7]. Reduced exercise cap-
acity in SCH may be due to impaired skeletal muscle
function and increased oxygen requirements of exer-
cise [8]. SCH may also cause a low-grade anaemia
[9]. The most convincing epidemiological associations
of SCH with disease states are with non-fatal and
fatal coronary heart disease events [10].
In contrast to the epidemiological associations with
poor health found in the whole population, SCH in very
old subjects (≥85 years) might be associated with better
health and survival compared to the euthyroid state, giv-
ing rise to the possibility of an age interaction for thy-
roid hormone effects [11].
The pituitary-thyroid axis is an evolutionary selected
key regulator to optimize developmental processes and
physiological responses to environmental stress. At the
same time TH might have a major role in the settlement
of the life-history trade-off between growth, metabolism,
and inflammation axes, which is required for homeosta-
sis maintenance. It is therefore feasible that survival be-
yond the reproductive phase is better off with lower
levels of thyroid hormone signalling, away from the opti-
mal characteristics that are generally required in the re-
productive part of life, with a lower rate of aging as a
result. Several experimental animal models are in agree-
ment with this hypothesis [12].
Evidence is lacking about the benefits of levothyroxine
replacement in the elderly with SCH, as no large RCT
on the full range of relevant clinical outcomes have been
performed [13]. The Cochrane systematic review of
levothyroxine replacement for SCH summarised the evi-
dence from RCTs up to 2006 [13]. It concluded that
there was some evidence for improved cardiac function
and blood lipids with levothyroxine replacement, but a
lack of data for improved survival, reduced cardiovascu-
lar morbidity or improved health-related quality of life;
data were available for only 350 patients in 12 RCTs,
often of short duration (range 6–14 months).
Subsequent RCTs of levothyroxine as an intervention
for patients with SCH (excluding during pregnancy)
have not resolved the clinical uncertainty, with generally
small and underpowered studies [4, 14–25]; the largest
sample size was 120 patients [26], and the longest mean
follow-up 14 months [27].
We are conducting a large RCT with power to detect
clinically worthwhile benefits from levothyroxine re-
placement for SCH. Critical elements of the study design
include recruitment of subjects with persisting SCH (ex-
cluding those in whom it is a temporary phenomenon,
who are less likely to benefit), long-term follow-up, and
a range of clinically important outcomes.
The primary outcomes are changes in 2 domains
(hypothyroid symptoms and fatigue / vitality) on the thy-
roid related quality of life questionnaire (ThyPRO) [28]
at 1 year (minimum follow-up). Secondary outcomes in-
clude general health-related quality of life (EuroQol)
[29], fatal and non-fatal cardiovascular events, handgrip
strength [30], executive cognitive function (Letter Digit
Coding Test) [31], basic [32] and instrumental activities
of daily living [33], haemoglobin, blood pressure, weight,
body mass index and waist circumference. Patients are
monitored for specific adverse events of interest includ-
ing incident atrial fibrillation, heart failure and bone
fracture. The study will also be used to establish a blood
bio-bank, to be used in future research into causes and
mechanisms of health, disease and disability in older
people with SCH.
There are four main study objectives:
1. Does Levothyroxine treatment for SCH give multi-
modal benefits for older people with SCH?
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2. Are benefits seen across a wide range of outcomes,
including prevention of cardiovascular disease, and
improving health-related quality of life, muscle func-
tion and cognition?
3. Are benefits seen in specific subgroups of older people
with SCH, including women, very elderly and those
with mild degrees of SCH (TSH 4.6–10 mU/L)?
4. Are any benefits offset by adverse effects, such as
atrial fibrillation or heart failure?
This manuscript represents the content of protocol
version 6.1, 24th March 2016.
Methods
This is a randomised double-blind placebo-controlled
parallel group trial of levothyroxine for older people with
SCH, with a minimum 1 year of follow-up.
Study population
The trial is running in four countries (UK, Ireland, the
Netherlands and Switzerland). Potential subjects are iden-
tified from clinical laboratory databases and recruited
from the community, aged ≥65 years with SCH, diagnosed
on the basis of persistently elevated TSH levels (4.6–
19.9 mU/L) with fT4 within the reference range. Baseline
and follow-up TSH was measured by clinical laboratories
affiliated with each clinical centre. TSH is measured on a
minimum of two occasions at least three months apart,
over a maximum period of 3 years. All subjects gave indi-
vidual informed consent to participate (See Appendix 1
and 2; Additional files 1 and 2 for model patient informa-
tion sheet and consent forms).
Exclusion criteria for the study:
i) Subjects currently prescribed Levothyroxine, anti-
thyroid drugs, amiodarone or lithium.
ii) Recent thyroid surgery or radio-iodine (within
12 months).
iii)Grade IV NYHA heart failure.
iv) Clinical diagnosis of dementia.
v) Recent hospitalisation for major illness or elective
surgery (within 4 weeks).
vi) Recent acute coronary syndrome, including
myocardial infarction or unstable angina (within
4 weeks).
vii)Acute myocarditis or pancarditis.
viii)Untreated adrenal insufficiency or adrenal disorder.
ix)Terminal illness.
x) Patients with rare hereditary problems of galactose
intolerance, the Lapp lactase deficiency or glucose-
galactose malabsorption.
xi) Subjects participating in ongoing RCTs of
therapeutic interventions (including Clinical Trials
of Investigational Medicinal Products; CTIMPs).
xii)Plan to move out of the region in which the trial is
being conducted within the next 2 years.
Randomisation
Subjects are allocated to levothyroxine or placebo (1:1)
with stratification by national site, sex and starting dose,
using the method of randomly permuted blocks. The
randomisation schedule is prepared by the data centre
(Robertson Centre, Glasgow), independent of the clinical
investigators. Implementation of the random allocation
sequence is by an independent party, Mawdsley Brooks
UK, who are responsible for packaging and labelling of
the Investigational Medicinal Product (IMP) and masked
to all other participant characteristics.
Enrolment of participants is done by study nurses,
under the supervision of a medically trained principal in-
vestigator at each site. Allocation of study number is
performed by central computer, with the decision trig-
gered by the study nurses using a dedicated study web-
site, following entering of eligibility data on an
electronic clinic record form.
Intervention
The IMP’s in this study are levothyroxine 25 and 50 mi-
crograms tablets and identical placebo tablets for oral
use. The tablets are white and round in shape with the
tablet strength imprinted on the active and matched pla-
cebo tablets. All tables are identical in taste and smell.
The tablets are manufactured and placed in blister strips
by the supplier Merck, in accordance with Good Manu-
facturing Practice; distribution to national study sites is
provided by Mawdsley Brooks UK.
The intervention starts with levothyroxine 50 micro-
grams daily (reduced to 25 micrograms in subjects
<50Kg body weight or if known coronary heart disease –
previous myocardial infarction or symptoms of angina
pectoris) versus matching placebo for 6–8 weeks. Pa-
tients are advised to take their prescribed dose once
daily in the morning before breakfast.
The dose is changed according to the serum TSH
level as follows; 6–8 weeks after randomisation a
blood sample is taken for serum TSH, with three pos-
sible actions:
1) TSH <0.4 mU/L: treatment dose reduced to 25
micrograms levothyroxine in those starting on 50
micrograms; reduced to 0 in those starting on 25
micrograms – blinding maintained by giving placebo
matching the 25 micrograms dose; these patients
will have a further check TSH after 6–8 weeks; if
TSH remains <0.4 mU/L patient will be withdrawn
from randomised treatment.
2) TSH ≥0.4 and <4.6 mU/L: no change to the
treatment dose; patient to be reviewed at 12 months.
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3) TSH remains elevated (≥4.6 mU/L): additional 25
micrograms levothyroxine, giving a total daily dose
of 75 micrograms levothyroxine for those starting on
50 micrograms, or a total daily dose of 50
micrograms levothyroxine for those starting on 25
micrograms.
Titration of dose of levothyroxine (25 micrograms incre-
ments) against serum TSH is repeated up to a maximum
of two occasions, at 6–8 week intervals, with a check of
serum TSH performed at 6–8 weeks after all dose titra-
tions. The investigators remained masked to the results of
TSH measurements throughout the course of the study.
The above process (but with only a single up-titration)
is repeated at 12 months (plus or minus 1 month) then
annually (at 24 and 36 months plus or minus 1 month).
The maximum possible dose of levothyroxine that is
prescribed is 150 micrograms.
A mock titration (by computer algorithm) is per-
formed in the placebo group aiming for approximately
the same frequency as that likely to be required in the
levothyroxine-treated group. We have adopted an adap-
tive schedule, in which the data centre allocates the
same proportion of placebo patients to have dose adjust-
ment (up and down) as are required in the levothyroxine
group. This ensures that the burden of assessment, and
number of tablets to be taken, is the same in both the
levothyroxine and placebo groups. The computer gener-
ated allocation also ensures that the clinical investigators
remain blind to treatment allocation.
Where a proposed up-titration of levothyroxine (or
placebo) is thought to be clinically inappropriate (e.g.
known non-adherence to IMP, recent major illness) the
algorithm is manually ‘over-ridden’ and the patient is
not up-titrated.
Criteria for withdrawal of participants on safety
grounds:
 If overt biochemical hypothyroidism is identified
(TSH ≥20 mU/L), the data centre requires a second
TSH measurement with fT4 within two weeks; if
overt biochemical hypothyroidism is confirmed (fT4
below reference range), the patient is required to
stop the trial medication and recommended to
attend GP for consideration of open treatment with
levothyroxine.
 If biochemical hyperthyroidism (TSH < 0.4 mU/L)
develops in the placebo group, or occurs at two
consecutive follow-up visits in a patient in the
levothyroxine group; i.e. persisting despite down-
titration of the levothyroxine dose, the patient will
stop the trial medication and attend their GP for
consideration of further assessment and treatment
of hyperthyroidism.
Blinding
The study is double blinded. Subject blinding to treat-
ment allocation is ensured through use of matched tab-
lets for levothyroxine and placebo, with a mock titration
in the placebo group (see above under intervention for
details). Clinician and study centre blinding to treatment
allocation is ensured by remote laboratory analysis of
blood samples for TSH and dose titration as per com-
puter algorithm.
All blood tests for in-study TSH and fT4 levels are per-
formed by the research team without knowledge of the re-
sults; all results from the follow-up phase of the study are
forwarded directly to the data centres who advise the clin-
ical research team on any dose titration. The clinical re-
search team are not informed of the results of thyroid
function testing. The same process of blinding is followed
for measurement of haemoglobin on a full blood count.
If the clinical investigator or attending physician
deems that unblinding is necessary they will have 24-hr
access to telephone unblinding through the data-centre.
In the event of a SUSAR, the sponsor (but not the inves-
tigators) will be unblinded to facilitate reporting to the
relevant regulatory authorities including the MHRA.
Descriptive study data and outcome measures
Descriptive data to be recorded at screening and /or
baseline are as follows:
(1)Age, sex and race.
(2)Lifestyle; smoking, alcohol intake.
(3)Known cardiovascular disease, including history of
coronary heart disease (angina pectoris or previous
myocardial infarction), cerebrovascular disease
(ischaemic stroke, transient ischaemic attack) or
peripheral vascular disease (intermittent
claudication), or any revascularisation procedure for
ischaemic vascular disease; history of atrial
fibrillation (AF); epilepsy; hypertension; diabetes
mellitus; osteoporosis.
(4)Prescribed medicines and over-the counter aspirin
or non-steroidal anti-inflammatory drugs will be re-
corded at each study visit; medicine count will be
used as an assessment of baseline co-morbidity.
(5)Mini-mental state examination (MMSE) score [34]
will be recorded at study baseline as a descriptor of
general cognitive function. However it will not be
repeated or used as an outcome measure as it is
insensitive to change over the time-span planned for
this study.
(6)Home support services (e.g. home help, meals-on-
wheels, district nursing) and home circumstances
(e.g. living alone, co-habiting, standard or sheltered
housing, or entry to care home), at study baseline
and final review.
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Primary study outcomes:
Initial plans were for joint primary study outcomes of
thyroid-specific quality of life and of incident cardiovas-
cular events. However, due to lower recruitment than
initially planned, the study is underpowered to detect an
effect on incident cardiovascular events and a formal
modification to protocol (including on the registered
trial protocol at clinicaltrials.gov) has been made to des-
ignate this as a secondary outcome.
Therefore the primary outcomes for the study are
thyroid-related quality of life and symptom burden as
measured by the ThyPRO hypothyroid symptoms score
and fatigue / vitality score measured at study baseline,
6–8 weeks and 12 months post-recruitment and at final
review [35]. The primary outcome is the change in the
score between baseline and one year. For disease-specific
and general quality of life, greatest effect will be ex-
pected after 1 year of treatment, and for these endpoints
this will be the primary time-point for analysis. In a sys-
tematic review of thyroid related quality of life assess-
ments ThyPRO was recommended as an appropriate
assessment tool for benign thyroid diseases [35].
Secondary study outcomes:
 General health-related quality of life (EuroQol-5D,
including the EuroQol visual anologue scale) [29].
Measured at study baseline, 6–8 weeks and
12 months post-recruitment and at final review.
 Comprehensive thyroid quality of life assessment
ThyPRO-39 [28] - recorded at final follow-up.
 Fatal and non-fatal cardiovascular events (acute
myocardial infarction; stroke; amputations for per-
ipheral vascular disease; revascularisations for ath-
erosclerotic vascular disease, including for acute
coronary syndrome, and heart failure
hospitalisations).
 Total mortality and cardiovascular mortality.
 Handgrip strength [30] (Jamar isometric
dynamometer - best of 3 measures in dominant
hand). Measured at study baseline, 12 months and
at final review.
 Executive cognitive function (letter digit coding test;
LDCT) [31]. Measured at study baseline, 12 months
and at final review.
 Functional ability (basic Activities of Daily Living
(ADL) measured using Barthel Index [BI] [36];
instrumental activities of daily living [33] measured
using the older American resources and services
[OARS] tool) [37]. Measured at baseline and final
follow-up.
 Haemoglobin measured on a full blood count at
baseline and 1 year.
 Blood pressure (systolic and diastolic). Measured at
screening / baseline, 12 months and at final review.
Measurements were made using an Omron 705IT,
after a minimum of 3 min sitting, using a standard
cuff (12–13 cm long and 35 cm wide) unless the
arm is very small or large, when an appropriate
alternative cuff size is determined by visual
assessment.
 Weight, waist circumference and body mass index.
Height, weight and waist circumference are
measured at screening / baseline; weight and waist
circumference are repeated at 12 months and at
final review.
See Figs. 1 and 2 for summary of timings of each
assessment.
Report forms for possible cardiovascular endpoints
and SAEs are generated for the study nurses to
complete; these are entered via the trial web portal
which has an in-built notification to the Endpoints Com-
mittee. Adjudicated endpoints are entered via the trial
web portal using separate adjudication record forms.
Anonymised source documents are uploaded by the
study nurses via the trial web portal, to assist in the ad-
judication process, in accordance with the committee’s
requirements.
Drug accountability data is gathered for each patient
including distribution date, quantity of study drug sup-
plied, and drug supply returns including date, and quan-
tity of tablets returned.
Biobank
Blood samples for the study biobank are collected at
baseline (40 ml venous blood) and at the 1 year visit
(10mls venous blood). Baseline bloods are stored in
0.75 ml aliquots as follows - 3 EDTA plasma, 1 whole
blood, 8 serum, 2 citrated plasma, 1 NaF plasma, 1 buffy
coat, 3 heparin plasma; total: 19 aliquots per patient at
baseline. One year bloods are stored in four 0.75 ml
serum aliquots per patient.
The TRUST biobank is the communal property of the
TRUST Executive Committee. The TRUST biobank is
organised through the TRUST Executive Committee by
the TRUST Biobank Committee. The TRUST Biobank
Committee has a representative from each TRUST site
and is approved by the TRUST Executive Committee. The
partners in this collaboration are the partners associated
with the trial’s principal investigators in Glasgow
(Scotland), Cork (Ireland), Bern (Switzerland), and Leiden
(Netherlands). All TRUST partners agree to the principles
outlined below in order to permit the optimum informa-
tion to be gained from exploitation of the Biobank.
The central location of the TRUST biobank is at the
Department of Clinical Chemistry of Leiden University
Medical Centre (LUMC), the Netherlands. The TRUST
biobank consists of (1) all plasma, serum and DNA
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samples from randomised TRUST participants held ei-
ther in the main biobank depository at LUMC or in the
local laboratories where TRUST samples are handled
during the study and (2) all data derived from analyses
of these samples.
The Department of Clinical Chemistry of the LUMC is
fully accredited by the Dutch Co-ordinating Committee
for Quality Control of Laboratories in Health Care.
Through the LUMC Department of Clinical Chemistry,
the TRUST biobank adheres to all quality assurance
standards that are necessary for a biobank. Furthermore,
for all legal issues the TRUST biobank adheres to local
(LUMC) and national guidelines. These guidelines cover
donor rights, re-identification of donors, and process for
removing samples from the biobank if a donor revokes
consent.
Fig. 1 Outcome variables and timings of assessments
Fig. 2 Levothyroxine dose titration flowchart. Levo-thyroxine dose is increased/decreased by 25 μg with a maximum dose of 150 μg. TSH
checked 6–8 weeks after every dose change until TSH is within the reference range of 0.4–4.6 mU/L. If TSH is found to be ≥20 mU/L, a second
TSH (and fT4) measurement is taken within 2 weeks. If a TSH of ≥20 mU/L is confirmed at second measurement then the patient is required to
stop the trial medication and attend GP for further investigation
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Access to the material of the biobank is gained by sub-
mitting a proposal in writing to the chair of the Biobank
Committee (PK). The chair will communicate the pro-
posal to the other members of the Biobank Committee
and together they will send a written proposal to the
TRUST Executive Committee. Once the proposal is ap-
proved by the TRUST Executive Committee, the oper-
ational aspects of obtaining material will be handled by
the Biobank group.
Study recruitment and sample size justification
In the initial study plans we aimed to recruit 3000
community dwelling subjects aged 65 years or over
with SCH. However due to a combination of factors
we were unable to achieve this number; these in-
cluded substantial delays in starting the study due
mainly to difficulties in procuring suitable supplies of
levothyroxine and matching placebo. Study recruit-
ment targets were revised (October 2014; by when
290 patients randomised) with an anticipated mini-
mum of 540 to be randomised; with an upscaling of
geographical areas for recruitment in all countries we
anticipated an increase up to a maximum of 750 pa-
tients randomised. Given the projections for recruit-
ment, revised power calculations were calculated for
minimum total recruitment number of 540 and a
maximum number of 750.
Hypothyroid symptom and fatigue / vitality domains
from the Thyroid-related Quality of Life patient-
reported outcome measure (ThyPRO) [38] are our
efficacy outcomes, and are given equal weights as co-
primary outcomes, with the required p-value for stat-
istical significance split equally to each (0.05/2 = 0.025
to each test). We assumed SDs for data at 1 year
values (adjusted for baseline) of 13.3 and 18.3 (on
100-point scales) for hypothyroid and fatigue / vitality
scales respectively. These SDs were justified on the
basis of an interim analysis of data on the 8th of
January 2015. We calculated 80% power to detect a
change with Levothyroxine treatment (versus placebo)
of 3.5 or 3.0 points on the hypothyroid scale and 4.9
or 4.1 points on the fatigue / vitality scale with total
sample sizes of 540 or 750 respectively. Personal
communication from the author of ThyPRO (Torquil
Watt) indicated that a 9 point change (100 point
scale) would be a realistic and clinically meaningful
effect size.
Retention of recruits was facilitated by offering flexibil-
ity in location of follow-up, and reasonable time win-
dows (plus or minus 1 month for the 12 month and
subsequent reviews) for review. Where patients elected
to withdraw from active treatment they were offered
follow-up, with recording of all study outcomes.
Data and statistical analysis
The data centre for the study is based in the Robertson
Centre for Biostatistics at the University of Glasgow.
This sits in the Glasgow Clinical Trials Unit, a UK
Clinical Research Collaboration fully registered Clinical
Trials Unit. The Centre has an ISO 9001/2008 quality
management system and TickIT, the corresponding
standard for software development.
The statistical analysis plan is presented as an
Additional file 3. Data will be summarised overall and by
treatment group. Continuous variables will be sum-
marised as number of observed values, number of miss-
ing values, mean and standard deviation, median and
interquartile range and minimum and maximum. Cat-
egorical data will be summarised as number of observed
values, number of missing values, number and percent-
age in each category.
Continuous efficacy outcomes involving measurement
at follow-up and baseline will be analysed at each time
point comparing treatment groups and adjusting for
stratification variables and baseline levels of the same
variable using linear regression. In addition, data items
measured at more than one follow-up time will be ana-
lysed using repeated measures regression analyses and in
terms of the final assessment for each participant. Con-
tinuous efficacy outcomes measured at final follow-up
only will be compared between treatment groups using
linear regression adjusting for stratification variables
(site, sex and starting dose of levothyroxine).
For all efficacy outcomes measured at baseline and
final visit, additional exploratory analyses that adjust for
time from baseline to final visit will be carried out. Dis-
tributions of the residuals will be reviewed and will be
taken into consideration in assessing whether or not
additional analyses based on transformations should be
carried out. When calculating ThyPRO scores, valid raw
total scores containing missing items will be scaled so
that the maximum possible score is maintained.
Time-to-event outcomes will be compared between
groups using Cox proportional hazards regression
models adjusting for stratification variables. Time to
event curves will be based on the Kaplan-Meier
method.
All efficacy analyses will be carried out on the
intention to treat (ITT) population. Safety analyses will
be carried out on the ITT population. The main analyses
will be modified ITT based on participants with data on
the outcome of interest. These analyses will be sup-
ported with sensitivity analyses using mixed effects
models and multiple imputations. Primary and second-
ary analyses will be repeated on the per protocol popula-
tion as exploratory analyses.
The primary and secondary outcomes at 12 months
will also be analysed in the following subgroups by
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adding the subgroup variable and its interaction with
treatment group:
 Sex (Male/Female)
 Baseline TSH
○ <10 / ≥10
○ <7 / 7–9.99 / ≥10
In addition, continuous interactions with age at ran-
domisation and baseline TSH will be analysed
analogously.
Study outcome analyses will be repeated on the per
protocol population as exploratory analyses.
Patient safety and adverse event recording
We have taken particular care in devising a titration al-
gorithm to avoid any possibility of prolonged periods of
thyroid hormone over replacement in those allocated to
levothyroxine. This should substantially reduce the risks
of adverse effects such as atrial fibrillation or cardiac
failure. In epidemiological studies these problems are
observed in association with biochemical hyperthyroid-
ism and not with TSH within the reference range. Simi-
larly for those allocated to placebo we have developed an
algorithm that is designed to detect those who develop
overt hypothyroidism are require to start open-label
levothyroxine. These measures are designed to ensure
safety of those who are randomised into the trial.
Within ThyPRO we are assessing the domain of hyper-
thyroid symptoms as a possible adverse effect (recorded
at baseline, 6–8 weeks, 12 months and final visit).
Adverse events (AEs) are recorded, notified, assessed,
reported, analysed and managed in accordance with the
Medicines for Human Use (Clinical Trials) Regulations
2004 (as amended). Certain potential adverse events are
anticipated or likely as a result of the study and study
population. The adverse events detailed below are likely
to occur in the context of over replacement of levothyr-
oxine. Our dose titration scheme and study processes of
careful monitoring of thyroid function tests are designed
to ensure we avoid prolonged periods of thyroid hor-
mone excess.
Full details of all AEs of special interest (new atrial fib-
rillation, heart failure, fractures, new diagnosis of osteo-
porosis) including the nature of the event, relationship
to study drug and outcome are recorded in the elec-
tronic case report form. AEs of special interest are moni-
tored and followed up until satisfactory resolution or
stabilization.
Atrial fibrillation (AF)
AF is associated with subclinical hyperthyroidism [39]
and therefore is a potential risk of thyroid over-
replacement for SCH. It should not occur if TSH is
maintained in the normal range, however we pay par-
ticular attention to identifying this possible adverse
event.
Cardiac rhythm is determined at study baseline, and
new onset AF, paroxysmal or persisting, is diagnosed
from an annual single-lead electrocardiograph, or if
noted on 12-lead electrocardiograph or telemetry per-
formed as part of hospitalisation or other clinical care,
or if identified by inquiry about hospitalisations and out-
patient visits (at all patient contacts). This general
process of screening for atrial fibrillation has been found
to be very sensitive for identifying new cases [40].
We use a single-lead recorder (Omron HeartScan
HCG-801-E). This provides a simple and quick as-
sessment of cardiac rhythm; it has been shown to
have high diagnostic accuracy for AF (sensitivity 99%,
specificity 96%) compared to a standard 12-lead elec-
trocardiograph [41].
Heart failure
Prevalent heart failure and incident heart failure diagno-
sis / hospitalisations will be recorded, as this outcome is
a potential risk of thyroid dysfunction and of thyroid
hormone over replacement [42].
Fracture
Musculoskeletal effects of Levothyroxine are described,
including osteopenia/ osteoporosis [6]. We record all
new fractures and all new diagnoses of osteoporosis.
Formal screening for osteoporosis is not required for
this trial.
Study monitoring and auditing
Study monitoring visits are conducted according to a
study-specific monitoring plan devised by NHS Greater
Glasgow and Clyde and subsequent monitoring reports
are reviewed by NHS Greater Glasgow and Clyde. At a
minimum, each site was monitored before the study
commenced (Study Initiation), study visit(s) and at the
end of the trial (Study Close Out Visit). Additional mon-
itoring visits were undertaken if required and the study
was subject to routine or for-cause audit visits. Investiga-
tors and site staff were notified in advance of any audit
and/or monitoring visits. Sponsors out-with the UK
identified the level of monitoring required and devel-
oped a monitoring plan, informed by the UK monitoring
plan.
Committees, role of sponsor / funder
The committee structure for the study included the fol-
lowing. The main decision making group for the study is
an Executive group of principle investigators (PIs) (Chair
Professor David J Stott; members Professor Ian Ford,
Professor Jacobijn Gussekloo, Professor Patricia M
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Kearney, Dr Nicolas Rodondi, Professor Rudi GJ Wes-
tendorp). The strategic planning and conduct of the
study is supervised by a Steering Committee (Chair Pro-
fessor David J Stott) which included the above PIs, plus
key ancillary partners; the PIs approved additional mem-
bers of the steering committee as required through the
study. This committee provided a discussion forum for
information to be shared, and opportunity given to influ-
ence the conduct of the study. National organising com-
mittees (chaired by the national PIs) supervised the
conduct of the trial in each of the 4 participating
countries.
The trial is subject to supervision by an Independ-
ent Data Monitoring Committee (IDMC). Members
are Professor Gary Ford (Chair; Chief Executive Offi-
cer of the Oxford Academic Health Science Network,
Oxford), Professor Thompson G Robinson (University
Hospitals of Leicester NHS Trust, Department of Car-
diovascular Sciences, Leicester Royal Infirmary,
Leicester), Professor Colin Dayan (Institute of Mo-
lecular and Experimental Medicine, Cardiff University
School of Medicine, Heath Park, Cardiff ), Professor
Kathleen Bennett (Department of Pharmacology and
Therapeutics, Trinity Centre for Health Sciences, St
James’s Hospital, Dublin). The primary responsibility
of the IDMC is to assess safety data in order to pro-
tect the ethical and safety interests of the subjects re-
cruited into the study, while safeguarding, as far as
possible, the scientific validity of the study. The
IDMC reviews information on the progress of the
trial and selected safety and efficacy data accruing
from the trial, but may request additional data if con-
sidered necessary in order to support the assessment
of relative risk and benefit within the study.
Members of the study Endpoint Committee are Pro-
fessor Peter Langhorne (Chair; Professor of Stroke Care,
Institute of Cardiovascular and Medical Sciences, Uni-
versity of Glasgow), Professor J Wouter Jukema (Vice-
chair; Professor of Cardiology, Leiden University Medical
Center, The Netherlands), Dr Tin Hai Collett (Depart-
ment of Ambulatory Care and Community Medicine,
University of Lausanne, Switzerland), Prof. Olaf M Dek-
kers Leiden University Medical Center, The Netherlands)
and Dr Anne Marie O’Flynn (Department of Epidemi-
ology and Public Health, UCC, Ireland). The role of the
Endpoint Committee is:
 To provide independent and unbiased review of
clinical endpoint events which occur during the
study.
 To ensure unified and unambiguous events
evaluation practices across the study, through
application of standardised event criteria, per
protocol specifications.
 To compensate for regional diversity in medical
practice in the area of endpoint evaluation and
classification, thereby reducing the impact of this
diversity.
This includes review and classification of all: causes of
death, strokes, myocardial infarctions, heart failure hos-
pitalisations, which are identified as potential clinical
endpoints.
The classification of endpoints is based on data from a
case report form and appropriate source documents.
The EPC is blinded to treatment allocation.
There is a TRUST Biobank committee consisting of
Professor Patricia M Kearney (chair), NS, H Anette van
Dorland (Berne, Switzerland), WPJdenE. This committee
advises the steering committee on storage and usage of
the TRUST biobank.
The primary co-sponsors of the study are NHS
Greater Glasgow and Clyde and University of Glasgow.
Prior to study initiation, a non-commercially funded
clinical trial co-sponsorship agreement was put in place
between NHS Greater Glasgow and Clyde and Univer-
sity of Glasgow. The role and liabilities each organisation
will take under Clinical Trials Regulations, 2004 (SI
2004:1031) are laid out in this agreement signed by both
organisations. The University of Glasgow is responsible
for carrying out the obligations and responsibilities set
out in the aforementioned agreement, and shall be
deemed “sponsor” for the purposes of Part 3 of the regu-
lations in relation to the study. NHS Greater Glasgow
and Clyde shall be responsible for carrying out the obli-
gations and responsibilities set out in the agreement,
and shall be deemed “sponsor” for the purposes of Parts
4, 5, 6 and 7 of the regulations in relation to the study.
Each participating member/associated state has desig-
nated a legal entity to operate as national sponsor. The
UK co-sponsors delegate sponsor responsibilities to each
identified legal entity and this is defined in a ‘Research
Agreement for the performance of an intergroup clinical
trial’. A fully executed agreement was implemented with
each participating member/associated state prior to the
TRUST study starting in that country. The sponsors
were responsible for ensuring appropriate indemnity and
insurance is in place to cover the liabilities arising from
trial conduct and participation. The sponsors of the
study take no role in the preparation or approval of sci-
entific outputs from this trial.
Merck KGaA have supported the study by providing
(free of any cost or charges) the medication, in form of
levothyroxine 50 microgram and 25 microgram tablets
and matching placebos. All supplies are manufactured in
accordance with current Good Manufacturing Practice
and in accordance with EU Directive 2001/20/EC. Merck
KGaA reserve the right to ask for deletion of any Merck
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confidential information. The views and opinions de-
scribed in this paper do not necessarily reflect those of
Merck KGaA.
Dissemination
We are in a strong position to ensure effective dissemin-
ation of the results of the TRUST study, including early
adoption into clinical practice. The patient advocacy
group Thyroid Federation International will play a key
role in planning the dissemination strategy and approv-
ing outputs to ensure methods and content fit with the
public need. Publications are approved through the
Steering Committee which involves representatives from
all partner organisations. It is anticipated that the main
study results will be announced at the Endocrine Society
Meeting in Orlando 1-4th April 2017.
We have a strategy for informing participant pa-
tients and their general health care practitioners. At
the final visit we determine what information the pa-
tient wishes to receive about their treatment in the
study. Communication to the patient and GP about
individual treatment is made normally within 15
working days after completion of the close-out visit.
Information provided for the patient’s health care
practitioner will include treatment allocation, final
dose (if on levothyroxine) and TSH level at final visit.
Unblinding of patient and their health care practi-
tioner requires either a member of the study team or
an independent medical advisor to be unblinded in
the course of release of information; these person(s)
are not involved in any way in measurement or re-
cording of study endpoints or subsequent adjudication
of SAEs (including gathering information or adjudica-
tion), either as possible vascular events or as events
that are being considered for expectedness or severity
for the MHRA or equivalent regulatory authority.
This minimises the risk of observer bias and ensure
the integrity of study data on SAEs is preserved.
We will provide access to the overall results of the
study and explain implications for clinical practice to
participating patients and for their health care practi-
tioners, with national stakeholder meetings in country
for supporting clinicians and patients; we also will an-
nounce the results using a study website. We aim for
these communications about the results of the study to
be within 1 month of the primary publication.
Discussion
The TRUST trial is the first large-scale multicentre RCT
of treatment of older people with SCH, comparing
levothyroxine with matching placebo. The study will
contribute substantially to knowledge on treatment of
SCH in older people, with good statistical power to de-
tect a meaningful effect on symptoms and thyroid-
related health-related quality of life. We anticipate the
main study results will be published in the Spring of
2017.
Appendix 1
Patient information sheet for screening
Title of Project: Thyroid hormone replacement for
subclinical hypothyroidism – the TRUST study.
You are invited to attend a screening visit for a research
study. The aim of the research is to determine if treating
subclinical hypothyroidism with thyroxine gives health
benefits to older people.
What is subclinical hypothyroidism?
Subclinical hypothyroidism means that the thyroid
gland, which is found in your neck, may not be produ-
cing the right amount of thyroid hormones that your
body needs to do its job well. Thyroid hormones are im-
portant as they help regulate different parts of the body,
including the circulation, heart, muscle and brain.
Subclinical means that there are no noticeable
symptoms or symptoms are at a level for which treat-
ment is not certain to be beneficial. Without a blood
test, it is impossible to know that you have subclinical
hypothyroidism.
What is the purpose of this screening?
Subclinical hypothyroidism is a common condition
among older men and women in Europe. A person
may have subclinical hypothyroidism, and experience
no symptoms. Subclinical hypothyroidism is not usu-
ally a serious health condition. The purpose of
screening is to identify people who are suitable to
take part in The TRUST Study. This is a study of the
effects of thyroxine replacement for older people with
subclinical hypothyroidism.
The TRUST Study
Some small studies have shown that when older people
with subclinical hypothyroidism take thyroxine supple-
ments their blood vessels become healthier and their
heart function improves. However, there may be un-
wanted side effects of thyroxine supplements too, these
may include an irregular heart beat (arrhythmia) and
bone thinning (osteoporosis) which can lead to an in-
creased risk of bone fracture.
The purpose of this study is to find out what effects
(good and bad) of thyroxine replacement have on older
people with subclinical hypothyroidism.
Why have I been invited to take part?
We are inviting people over the age of 65 who have had a
recent blood test at their doctors the results of which sug-
gest that they may have subclinical hypothyroidism and
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therefore may be suitable to take part in the TRUST
Study. We have asked your GP or hospital doctor for per-
mission to approach you about taking part in screening
for the TRUST Study and they have agreed. However, it
important to note that your GP or hospital doctor has no
other involvement with this study.
Do I have to take part?
You are not in any way obliged to take part - it is up to
you to decide. If you do decide to take part you will be
asked to sign a consent form for screening for the study.
Even if you decide to take part you are still free to with-
draw at any time and without giving a reason. This will
not affect the standard of care you receive.
What will happen to me if I take part?
If you decide that you are interested in taking part in
screening, you will be asked to sign a consent form.
Then you would be invited to a screening visit at your
GP surgery or local hospital Clinical Research Facilities,
at a time that suits you. However, you may prefer to be
assessed at home and this can be arranged with the
study nurse. The screening visit would take place up to
six weeks before the study starts and will last up to 30
min. The purpose of screening is to decide if you are eli-
gible to take part in the TRUST study. To decide this,
you would be asked some medical questions, your blood
pressure, height, weight and waist circumference would
be measured and a blood test would be taken. We would
also collect some information from your medical record
(paper-based and computerised), held by your GP or
hospital; examples include information about your diag-
noses, lab results, medical procedures, and medications).
This is because we need to know if you have any prob-
lems with your health.
If the results from the screening tests and medical rec-
ord examination are satisfactory you would be invited to
take part in the TRUST study. The blood results from
this visit will be available within 1 week. If these confirm
that you are suitable to take part in the study you will be
sent further details by post including a written invitation
to take part in the treatment phase of the study. You will
be informed in writing if you are not suitable for entry
into the treatment phase of the study, with the reasons
explained. If we find a medical condition of which you
are unaware (e.g. high blood pressure), we will inform
you, and write to your GP.
If you are suitable to take part in the full study, and
decide to take part, the drug that will be tested is
Levothyroxine, given as a capsule and taken by mouth.
The purpose of the TRUST study is to determine
whether there are benefits and drawbacks of giving
Levothyroxine to older people with subclinical
hypothyroidism.
We will follow up the long-term health outcomes of
all people who are screened for entry into the TRUST
trial, whether or not they enter the treatment phase of
the study. We plan to do this by looking at routinely re-
corded health information held by the NHS and records
maintained by the General Register Office in Scotland.
Your paper and computerised health records will be
used by the University of Glasgow to follow up your fu-
ture long-term health status. This will include paper and
computerised records held by the NHS and electronic
records maintained by the General Register Office at the
Scottish Government.
If you are suitable to enter the full study, and decide
to take part, the drug that will be tested is levo-
thyroxine, given as a tablet orally (by mouth). We are
testing whether it gives benefits to older people with a
mildly underactive thyroid.
Reasons we might not ask you to take part in the
study
If you are on certain drugs that affect thyroid blood tests
or how the thyroid works, such as lithium, amiodarone,
carbimazole or levothyroxine then it would not be ap-
propriate for you to enter the study.
If your repeat thyroid blood tests show that your thy-
roid gland is now working normally, you then do not
need any treatment and it would not be appropriate for
you to enter the trial. On the other hand if your blood
tests show your thyroid gland is now very underactive,
then you will be advised to discuss these results with
your GP, and it is likely you will require thyroid hor-
mone treatment; it would not then be appropriate for
you to enter the study.
Long-term follow-up of your health
We will follow up the long-term health outcomes of all
people who are screened for entry into the TRUST trial,
whether or not they enter the treatment phase of the
study. We plan to do this by looking at routinely re-
corded health information held by the NHS and records
maintained by the General Register Office in Scotland.
Your paper and computerised health records will be
used by the University of Glasgow to follow up your fu-
ture long-term health status. This will include paper and
computerised records held by the NHS and electronic
records maintained by the General Register Office at the
Scottish Government.
Will my expenses be paid?
Travel expenses will be provided to cover the cost of at-
tending your visit.
Will my taking part in this study be kept
confidential?
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All information which is collected about you will be kept
strictly confidential. We will keep your personal details
on a secure computer at Glasgow University and the
Clinical Research Facility. This is required to allow us to
communicate with you (e.g. by post or telephone), and
for us to link to the routine health information that is
held by the Scottish Government.
However your name and contact details will not be
disclosed to any other people, other than to your GP or
hospital doctor who is providing care to you. Your GP
and any hospital doctors who are caring for you will be
notified of your screening for participation in the trial.
Agreement from you that your GP can be informed is a
condition of entering the study.
Any information which leaves your GP surgery or hos-
pital will have your contact details, including name and
address, removed so that you cannot be recognised from
it. Your anonymised details and results will be shared
with our collaborating investigators in the Netherlands,
Ireland, Switzerland and the USA.
Who is organising and funding the research?
The organisation funding the research is the
European Union. The team conducting the research
in Scotland is from the University of Glasgow (linking
with Greater Glasgow Health Board); this research is
in collaboration with Leiden University Medical
Centre in the Netherlands, Cork in Ireland, and Uni-
versity of Berne in Switzerland. We are also collabor-
ating with thyroid experts from the University of
California in the USA.
Contacts for Further Information
Further information can be obtained through the study
freephone 0800 328 0772, or on the study website
(www.trusthyroidtrial.com).
General information about thyroid problems can be
found on the Thyroid Federation International website
at www.thyroid-fed.org.
The doctors who are running the clinical aspects of
the study in Scotland are;
Professor David J Stott and Dr Terence J Quinn,
Academic Section of Geriatric Medicine,
Institute of Cardiovascular and Medical Sciences,
University of Glasgow,
4th floor Walton building Glasgow Royal Infirmary G4
0SF.
Appendix 2
Participant information sheet for randomisation
Patient information sheet for the trust study
Thyroid hormone replacement for subclinical
hypothyroidism – the TRUST study.
Invitation paragraph:
You are being invited to take part in a research study.
Before you decide whether or not to take part it is im-
portant for you to understand why the research is being
done and what it will involve. Please take time to read
the following information carefully and discuss it with
friends, relatives and your GP if you wish. Ask us if there
is anything that is not clear or if you would like more in-
formation. Thank you for reading this information sheet.
Background
You have been asked to take part in this study be-
cause your recent screening blood test has told us
that you have subclinical hypothyroidism. Subclinical
hypothyroidism means that the thyroid gland, which
is found in your neck, is not producing the right
amount of thyroid hormones that your body needs to
do its job well. Thyroid hormones are important as
they help regulate different parts of the body, includ-
ing the circulation, heart, muscle and brain. Subclin-
ical means that there are no noticeable symptoms.
Without a blood test, it is impossible to know that
you have subclinical hypothyroidism. Subclinical
hypothyroidism is a common condition among older
men and women affecting up to 1 in 6 of over-65s.
How many people like me (participants) will be
taking part in this study?
There would be up to 750 people enrolled in this study
from Scotland, Ireland, The Netherlands and
Switzerland.
What is the purpose of the study?
We aim to determine whether treating subclinical
hypothyroidism with Levothyroxine gives health benefits
to older people. Small studies have reported less fatty
lining in blood vessels (atherosclerosis) and improved
heart function with medication (Levothyroxine), but no
large clinical trials have been performed. However, there
may be unwanted side effects of Levothyroxine supple-
ments too, these include an irregular heart beat
(arrhythmia) and bone thinning (osteoporosis) which
can lead to an increased risk of bone fracture.
The purpose of this study is to find out what effects
(good and bad) of Levothyroxine replacement have on
older people with subclinical hypothyroidism. We are in-
terested in how well Levothyroxine works to:
 prevent heart and circulatory system problems
(such as stroke)
 improve muscle function (such as strength)
 improve health related quality of life (by reducing
symptoms such as tiredness)
 improve speed of thinking
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You would be monitored carefully to ensure that you
are not over-medicated with Levothyroxine; we believe
this is important to reduce the risk of any side effects.
Why have I been chosen?
You have been chosen to be invited to take part in
this study as your blood tests have shown that you
have a mildly underactive thyroid gland with no
symptoms or with symptoms at a level that treatment
is not certain to be beneficial, and you are 65 years
of age or older. You have had a screening assessment
that has shown that your thyroid blood tests remain
mildly underactive and you are suitable to enter the
study.
Do I have to take part?
You are not in any way obliged to take part - it is up to
you to decide. If you do decide to take part you will be
asked to sign a consent form. Even if you decide to take
part you are still free to withdraw at any time and with-
out giving a reason. This will not affect the standard of
care you receive.
If I agree to take part, will I get the Levothyroxine
drug?
Once you have completed all the baseline information
you will be assigned either to receive daily Levothyr-
oxine, or to receive a placebo. A placebo is a pill
which looks, tastes and smells like the real thing but
is not; it contains no active ingredient. You will be
assigned to one group or the other using a process of
randomization. Randomization means that you have
the same chance of being assigned to the Levothyrox-
ine group or the placebo group. It is like tossing a
dice or flipping a coin. This helps to make sure that
the patients in each group (Levothyroxine or placebo)
of the study are roughly the same, so that we can be
sure that we get the correct answer to the question
that the study is asking. If you chose to enter the
study you would have a 50:50 chance of getting
Levothyroxine or placebo. A computer will choose
which group you are put in. Neither you, the doctors,
study nurses or any of the people involved in the
study will choose or know what group you will be in
(although, if your doctor needs to find out he / she
can do so).
What else will happen to me if I take part?
The first (baseline) study visit will be at your GP
surgery or at your local hospital Clinical Research
Facilities (if it suits you better, this can be done at
your own home). We anticipate this visit will last for
60–90 min.
This assessment will include:
 Check of any new medical problems, changes to
your medicines or home circumstances.
 A heart rhythm check, using an electronic recorder.
To do this the research nurse will instruct you to
hold a recording box in one hand, and press it
gently over the front-left side of your chest for 30 s.
 Assessment of your quality of life, using 2 thyroid
symptom questionnaires and a general quality of
life questionnaire.
 Measurement of your grip strength; you will be
asked to squeeze a portable grip measure machine
as hard as you can, 3 times in succession.
 A 30-point memory questionnaire.
 Measurement of your speed of thinking, using a
paper exercise taking 1 min.
 Assessment of how you are managing in everyday
activities, using an Activities of Daily Living
questionnaire, and how you are managing socially
using a short questionnaire.
A blood sample (equivalent to 8 teaspoons) will then
be taken to measure your blood count and to store
blood for future laboratory analysis of factors that pre-
dict future illnesses; this will include storage of your
genes (DNA) to allow us to examine any inherited fac-
tors that lead to illness in later life. A further small sam-
ple (equivalent to 3 teaspoons) will be repeated one year
later, and stored for future research on the effects of thy-
roid hormone. You have the option of opting out of this
part of the study if you wish.
Some of the above measures (general quality of life,
speed of thinking and grip strength) and taking extra
blood for future laboratory analysis will only be done in
some of the research sites – so you may not be offered
these tests.
You will be reviewed face-to-face by the study nurses
at 6 to 8 weeks and 12 months then annually up to a
maximum of 3½ years. In addition the study nurses will
contact you by telephone at interim periods; 6, 18 and
30 months. It is anticipated that the review visits will
take around 30 min, and telephone calls 15 min.
At all of these contacts the study nurses will enquire
about any new illnesses or changes to your usual
medicines.
At 6 to 8 weeks, 12 months, and annually thereafter, a
blood test (volume 2 teaspoons) will be taken to check
your thyroid levels. This is to ensure that if you are
treated with levothyroxine we give you the right dose; if
you receive placebo we will know that your thyroid is
not slowing down further – if this occurs you will re-
quire review by your GP. If your thyroid tests need ad-
justments to be made to your dose of tablets you will be
asked to return for a further blood test in 6 to 8 weeks.
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A member of the research team may contact you via
telephone to confirm that you have received the study
medicines.
 The heart rhythm check will be repeated annually
and at your final visit.
 The quality of life measurements will be repeated at
6 to 8 weeks and at 12 months and at your final
visit.
 The hand-grip measure and blood pressure
(blood pressure was checked at screening visit)
will be repeated at 12 months and at your final
visit.
 Your weight and waist circumference which was
checked at the screening visit will be repeated at 12
months and at your final visit
 The speed of thinking paper exercise, and
questionnaires on activities of daily living, social
function, and home circumstances and support will
be repeated at your final visit.
Travel expenses will be provided to cover the costs of
attending all your visits.
The total duration of the study is 5 years (finishing in
2017). If you take part in the study your personal partici-
pation will be for at least 1 year, and could be as long as
3 ½ years (42 months).
What do I have to do?
During the study you will be asked to take between 1
and 3 tablets, once every day, and attend the study visits
as listed above, including reporting any illnesses or side
effects. There are no lifestyle restrictions or dietary re-
strictions from taking part in this study. You will still be
able to drive, take part in sport, or give blood, should
you wish to do so. During the study you should continue
to take your regular medication.
What is the drug that is being tested?
The drug that is being tested is Levothyroxine, given as
a tablet orally (by mouth). This is a hormone that occurs
naturally in the body. It is the standard treatment when
there is no doubt that the thyroid gland is underactive.
Levothyroxine is used by between 3 and 5% of the popu-
lation. We are testing whether it gives benefits to older
people with a mildly underactive thyroid.
We will start the treatment with a low dose either
25ug or 50ug. The dose will be reviewed at 6 to 8 weeks
and 12 months then annually. Adjustments will be made
depending on a thyroid blood test; some people will re-
quire an increase, and some a decrease. Over the course
of the study the dose will be increased to a maximum of
3 tablets per day (150ug). Similar adjustments will be
also be made for some people in the placebo group, to
ensure that people do not guess which group they have
been allocated to.
What are the alternatives for treatment?
The main options for people with a mildly underactive
thyroid gland are either to start Levothyroxine tablets,
or to be followed up with no treatment. In either case a
regular (e.g. annual) blood test is usually required.
What are the possible side effects of Levothyroxine?
Side effects from levothyroxine treatment are only rarely
seen, particularly if blood tests are done regularly and
adjustments to Levothyroxine dose are made to keep
thyroid hormone levels in the normal range. If Levothyr-
oxine is prescribed in too high a dose there is a risk of
side effects. These could include development of an ir-
regular heart rhythm called atrial fibrillation. This can
cause tiredness, shortness of breath and an increased
risk of stroke. Increased strain on the heart with exces-
sive thyroxine doses could worsen angina (chest pain
coming from the heart) or cause breathlessness and leg
swelling. If you are overmedicated with thyroxine there
may be an increased risk of thinning of bones (osteopor-
osis) and fractures.
If you are on an anticoagulant it is possible that the
dose may need to be adjusted to prevent your blood be-
coming too thin. If you have diabetes there is a possibil-
ity that starting on levothyroxine might require an
increase in dosage requirements of insulin or other anti-
diabetic therapy. If you are taking anti-depressant tablets
there is a possibility of abnormal heart ryhthms.
However these problems are unlikely so long as we do
regular blood tests to ensure that we do not overmedi-
cate you.
For those allocated to the inactive tablets (placebo)
there is a risk that their thyroid gland may slow down
further, and they may develop symptoms of an underac-
tive thyroid, including tiredness and lethargy.
Taking blood samples may cause slight discomfort and
there may be a small chance of local bruising afterwards.
What are the possible disadvantages and risks of taking
part?
If you have private medical insurance you should check
with the company before agreeing to take part in the
trial. You will need to do this to ensure that your med-
ical insurance will not be affected.
What are the possible benefits of taking part?
Benefits to individual patients who take part in this
study cannot be guaranteed. Even if it does not help you
directly, the information we get from this study should
help us make better decisions on treatment of future pa-
tients with subclinical hypothyroidism. If during the
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study, we find a medical condition of which you are un-
aware (e.g. high blood pressure), we will inform you and
we will write to and inform your GP.
What if new information becomes available?
Sometimes during the course of a research project, new
information becomes available about the treatment that
is being studied. If this happens, your research doctor
will tell you about it and discuss with you whether you
want to continue in the study. If you decide to withdraw
your research doctor will make arrangements for appro-
priate care to continue through your GP. If you decide
to continue in the study you will be asked to sign an up-
dated consent form.
Also, on receiving new information your research doc-
tor might consider it to be in your best interest to with-
draw you from the study. If this happens he / she will
explain the reasons and arrange for your care to con-
tinue through your GP.
What happens when the research study stops?
When the research study stops your supply of study
medicines will finish, and you will return any unused
capsules to the research nurse. It is likely that the full re-
sults will not be available for several months. You and
your GP will then be informed in writing of the key re-
sults of the study, and also which group you were in
(Levothyroxine or placebo capsules).
After the study finishes there will then be a decision to
make as to whether you then take Levothyroxine tablets
as part of your routine care. This will be your decision,
which you should make in consultation with your GP.
The study freephone will continue to be available for a
minimum of 6 months after the study finishes; you will be
able to use this to arrange to speak to one of the research
doctors for further information or advice, should you wish.
After the study finishes the research team will con-
tinue to gather routine healthcare information about
your hospital admissions and diagnoses, to enable fur-
ther research to be done on long-term health outcomes
in older people with subclinical hypothyroidism.
What if something goes wrong?
There are no special compensation arrangements if
something goes wrong when you are taking part in this
research project however you will receive the same legal
protection as a standard National Health Service patient.
If you are harmed due to someone’s negligence, then
you may have grounds for legal action but you may have
to pay for it. Regardless of this, if you wish to complain
about any aspect of the way you have been approached
or treated during the course of this study, the normal
National Health Service complaints mechanisms will be
available to you.
Will my taking part in this study be kept
confidential?
All information which is collected about you will be kept
strictly confidential. We will keep your personal details
on a secure computer at Glasgow University and the
Clinical Research Facility. This is required to allow us to
communicate with you (e.g. by post or telephone), and
for us to link to the routine health information that is
held by the Scottish Government.
However your name and contact details will not be
disclosed to any other people, other than to your GP or
hospital doctor who is providing care to you. Your GP
and any hospital doctors who are caring for you will be
notified of your screening for participation in the trial.
Agreement from you that your GP can be informed is a
condition of entering the study.
Any information which leaves your GP surgery or hos-
pital will have your contact details, including name and
address, removed so that you cannot be recognised from
it. Your anonymised details and results will be shared
with our collaborating investigators in the Netherlands,
Ireland, Switzerland and the USA.
What will happen to the results of the research
study?
The results of the main part of the research should be
available within 6 months of you completing the study,
and it is expected the primary publication will be within
12 months. You and your GP will be informed in writing
of the key results of the study (anticipated between 6
and 12 months after you finishing in the study), and also
which group you were in (thyroxine or placebo tablets).
The results and details of publications will also be placed
on the study website, at the time of publication. You will
not be identified in any report or publication.
Who is organising and funding the research?
The organisation funding the research is the European
Union. The team conducting the research in Scotland is
from the University of Glasgow (linking with Greater
Glasgow Health Board); this research is in collaboration
with Leiden University Medical Centre in the
Netherlands, Cork in Ireland, and University of Berne in
Switzerland. We are also collaborating with thyroid
experts from the University of California in the USA.
Who has reviewed the study?
The research project has been reviewed by, and received
approval from the following;
 The European Union grant reviewers (includes
ethical review).
 The Scottish Multicentre Research Ethics
Committee (MREC A).
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 Thyroid Federation International, the umbrella
organisation for patient support groups for those
with thyroid disorders. It aims to work for the
benefit of those affected by thyroid disorders
throughout Europe and the world.
Contacts for Further Information
Further information can be obtained through the study
freephone 0800 328 0772or on the study website
(www.trusthyroidtrial.com). General information about
thyroid problems can be found on the Thyroid Feder-
ation International website at www.thyroid-fed.org. The
doctors who are running the clinical aspects of the study
in Scotland are; Professor David J Stott and Dr Terence
J Quinn, Academic Section of Geriatric Medicine, Insti-
tute of Cardiovascular and Medical Sciences, University
of Glasgow, 4th floor Walton building Glasgow Royal In-
firmary G4 0SF.
Additional files
Additional file 1: Participant consent form for screening. (DOC 79 kb)
Additional file 2: Patient consent form for randomisation. (DOC 64 kb)
Additional file 3: Statistical analysis plan. (DOCX 45 kb)
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